Australia's most trusted
source of pharma news
Tuesday, 29 April 2025
Posted 3 April 2023 AM
The TGA has waved through a slew of new drugs, including Australia's first-ever RET inhibitor.
Roche's soon to be offloaded Gavreto has been provisionally approved for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.